The multi-factorial nature of clinical multidrug resistance in cancer
Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
Organic cation transporters in health and disease
H Koepsell, LC Daws - Pharmacological reviews, 2020 - Elsevier
The organic cation transporters (OCTs) OCT1, OCT2, OCT3, novel OCT (OCTN) 1, OCTN2,
multidrug and toxin exclusion (MATE) 1, and MATE kidney-specific 2 are polyspecific …
multidrug and toxin exclusion (MATE) 1, and MATE kidney-specific 2 are polyspecific …
Cancer drug resistance: A brief overview from a genetic viewpoint
J Rueff, AS Rodrigues - Cancer Drug Resistance: Overviews and Methods, 2016 - Springer
Cancer drug resistance leading to therapeutic failure in the treatment of many cancers
encompasses various mechanisms and may be intrinsic relying on the patient's genetic …
encompasses various mechanisms and may be intrinsic relying on the patient's genetic …
QSAR modeling and molecular docking studies of 2-oxo-1, 2-dihydroquinoline-4-carboxylic acid derivatives as p-glycoprotein inhibitors for combating cancer …
Multidrug resistance (MDR) proteins related to the ATP-binding cassette family are found in
a very wide range of human tumors and result in therapeutic failure. The overexpression of …
a very wide range of human tumors and result in therapeutic failure. The overexpression of …
Impact of membrane drug transporters on resistance to small-molecule tyrosine kinase inhibitors
C Neul, E Schaeffeler, A Sparreboom, S Laufer… - Trends in …, 2016 - cell.com
Small-molecule inhibitors of tyrosine kinases (TKIs) are the mainstay of treatment for many
malignancies and represent novel treatment options for other diseases such as idiopathic …
malignancies and represent novel treatment options for other diseases such as idiopathic …
OCT1 and imatinib transport in CML: is it clinically relevant?
Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML)
patients; however, responses to frontline imatinib are variable. The human organic cation …
patients; however, responses to frontline imatinib are variable. The human organic cation …
The human organic cation transporter OCT1 and its role as a target for drug responses
N Brosseau, D Ramotar - Drug metabolism reviews, 2019 - Taylor & Francis
The human organic cation uptake transporter OCT1, encoded by the SLC22A1 gene, is
highly expressed in the liver and reported to possess a broad substrate specificity. OCT1 …
highly expressed in the liver and reported to possess a broad substrate specificity. OCT1 …
Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis
ZP Jiang, XL Zhao, N Takahashi, S Angelini… - …, 2017 - Taylor & Francis
Aim: The present study aimed to conduct a series of meta-analyses to investigate the
influence of imatinib trough concentration (C0), as well as ABCB1 and ABCG2 …
influence of imatinib trough concentration (C0), as well as ABCB1 and ABCG2 …
Drug resistance-related competing interactions of lncRNA and mRNA across 19 cancer types
Drug resistance is a common cause of treatment failure in cancer therapy, and molecular
mechanisms need further exploration. Competing endogenous RNAs (ceRNAs) can …
mechanisms need further exploration. Competing endogenous RNAs (ceRNAs) can …
MicroRNAs and cancer drug resistance
BC Gomes, J Rueff, AS Rodrigues - Cancer Drug Resistance: Overviews …, 2016 - Springer
The discovery of small regulatory noncoding RNAs revolutionized our thinking on gene
regulation. The class of microRNAs (miRs), a group of small noncoding RNAs (20–22 nt in …
regulation. The class of microRNAs (miRs), a group of small noncoding RNAs (20–22 nt in …